drugset
drugset / Trial / NCT01766050

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

NCT01766050 ↗

Phase 4 Completed 45 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine the effects of belatacept on the pharmacokinetics of caffeine, losartan, omeprazole, dextromethorphan and midazolam

Timeline

Start
2013-01
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Belatacept Protein / enzyme biologic 10 mg/kg Intravenous
Subject Caffeine Small molecule 200 mg Oral
Subject Dextromethorphan Unknown 30 mg Oral
Subject Losartan Other / unclassified 50 mg Oral
Subject Midazolam Small molecule 5 mg Oral
Subject Omeprazole Other / unclassified 40 mg Oral

Indications

transplant rejection